- Home
- EOG vs TAK Comparison
EOG vs TAK Comparison
Compare EOG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOG | TAK |
|---|---|---|
| Founded | 1985 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6B | 59.8B |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EOG | TAK |
|---|---|---|
| Price | $163.51 | $20.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 33 | 3 |
| Target Price | ★ $164.41 | $22.77 |
| AVG Volume (30 Days) | 2.4M | ★ 2.5M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.58% | 2.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.84 | N/A |
| Revenue | ★ $22,632,000,000.00 | N/A |
| Revenue This Year | $33.94 | $4.40 |
| Revenue Next Year | N/A | $1.95 |
| P/E Ratio | ★ $17.85 | $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $101.59 | $12.99 |
| 52 Week High | $160.31 | $20.39 |
Technical Indicators
Market Signals| Indicator | EOG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 76.64 | 70.39 |
| Support Level | $127.38 | $17.58 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.50 | 0.28 |
| MACD | 1.37 | 0.17 |
| Stochastic Oscillator | 92.87 | 94.46 |
Price Performance
Historical ComparisonAbout EOG EOG Resources Inc.
EOG Resources is an oil and gas producer with acreage in several US shale plays, primarily in the Permian Basin and the Eagle Ford. At the end of 2024, it reported net proven reserves of 4.7 billion barrels of oil equivalent. Net production averaged roughly 1,232 thousand barrels of oil equivalent per day in 2025 at a ratio of 69% oil and natural gas liquids and 31% natural gas.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.